Search research articles
Contact Us
Filters
Showing results (181-190 of 259) with videos related to
Page
of 26
Sort By:
Oncogene
|
October 29, 2021
Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity
Chaïma Cherif, Dang Tan Nguyen, Clément Paris, et al.
Oncogene
|
October 29, 2025
Correction: Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity
Chaïma Cherif, Dang Tan Nguyen, Clément Paris, et al.
The Lancet. Oncology
|
March 12, 2017
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial
Kim N Chi, Celestia S Higano, Brent Blumenstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 2, 2026
Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer
Martin Smoragiewicz, Alice Bernard-Tessier, Mark Linch, et al.
NEJM Evidence
|
February 6, 2024
Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer
Stephen J Freedland, Martin Gleave, Ugo De Giorgi, et al.
Oncotarget
|
June 9, 2016
Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor
Daniel J Coleman, Kathryn Van Hook, Carly J King, et al.
European Urology
|
November 7, 2020
Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors
Lucia Nappi, Marisa Thi, Nabil Adra, et al.
Molecular Oncology
|
October 21, 2019
The molecular function of kallikrein-related peptidase 14 demonstrates a key modulatory role in advanced prostate cancer
Thomas Kryza, Nathalie Bock, Scott Lovell, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
December 19, 2016
Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in <sup>68</sup>Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI
Martin T Freitag, Jan P Radtke, Ali Afshar-Oromieh, et al.
Urology Practice
|
May 5, 2023
Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS Cohort
Adrian J Waisman Malaret, Peter Chang, Lisa Newcomb, et al.
Page
of 26
Search research articles
Search
Showing results (181-190 of 259) with videos related to
Sort By:
Page
of 26
Oncogene
|
October 29, 2021
Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity
Chaïma Cherif, Dang Tan Nguyen, Clément Paris, et al.
Oncogene
|
October 29, 2025
Correction: Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity
Chaïma Cherif, Dang Tan Nguyen, Clément Paris, et al.
The Lancet. Oncology
|
March 12, 2017
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial
Kim N Chi, Celestia S Higano, Brent Blumenstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 2, 2026
Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer
Martin Smoragiewicz, Alice Bernard-Tessier, Mark Linch, et al.
NEJM Evidence
|
February 6, 2024
Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer
Stephen J Freedland, Martin Gleave, Ugo De Giorgi, et al.
Oncotarget
|
June 9, 2016
Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor
Daniel J Coleman, Kathryn Van Hook, Carly J King, et al.
European Urology
|
November 7, 2020
Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors
Lucia Nappi, Marisa Thi, Nabil Adra, et al.
Molecular Oncology
|
October 21, 2019
The molecular function of kallikrein-related peptidase 14 demonstrates a key modulatory role in advanced prostate cancer
Thomas Kryza, Nathalie Bock, Scott Lovell, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
December 19, 2016
Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in <sup>68</sup>Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI
Martin T Freitag, Jan P Radtke, Ali Afshar-Oromieh, et al.
Urology Practice
|
May 5, 2023
Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS Cohort
Adrian J Waisman Malaret, Peter Chang, Lisa Newcomb, et al.
Page
of 26